EUVIMEDEUVIMED entdecken
Crossref

English version of Japanese guidance for the use of oral Janus kinase inhibitors ( JAK1 and TYK2 inhibitors) in the treatments of psoriasis

Hidehisa Saeki iD, Tomotaka Mabuchi, Akihiko Asahina iD, Masatoshi Abe, Atsuyuki Igarashi, Shinichi Imafuku iD, Yukari Okubo iD, Mayumi Komine iD, Kenzo Takahashi, Hideshi Torii iD, Akimichi Morita iD, Hiroshi Yotsuyanagi und 3 weitere

The Journal of Dermatology · 2023

DOI: 10.1111/1346-8138.16797 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Dermatology, 2023. Verfasst von Hidehisa Saeki und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Nippon Medical School, Tokyo, Japan. Hauptthemen laut MEDLINE: Arthritis, Psoriatic, Janus Kinase Inhibitors, Psoriasis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This is the English version of Japanese guidance for the use of oral Janus kinase (JAK) inhibitors (JAK1 and tyrosine kinase 2 [TYK2] inhibitors) in the treatments of psoriasis. Several cytokines, such as interleukin (IL)‐6, IL‐7, IL‐12, IL‐21, IL‐22, IL‐23, interferon (IFN)‐α, and IFN‐γ, are involved in the pathogenesis of psoriasis (including psoriatic arthritis). As oral JAK inhibitors hinder the JAK‐signal transducers and activators of transcription signal transduction routes involved in the signal transduction of these cytokines, they may be effective for the treatment of psoriasis. JAK has four types: JAK1, JAK2, JAK3, and TYK2. Regarding the use of oral JAK inhibitors for the treatment of psoriasis in Japan, indications of the JAK1 inhibitor upadacitinib were extended also to psoriatic arthritis in 2021, and the use of the TYK2 inhibitor deucravacitinib for plaque‐type psoriasis, pustular psoriasis, and erythrodermic psoriasis became covered by health insurance in 2022. This guidance was developed for board‐certified dermatologists who specialize in the treatment of psoriasis and to promote the proper use of oral JAK inhibitors. In the package inserts and guides for appropriate use, upadacitinib and deucravacitinib are classified as a “JAK inhibitor” and a “TYK2 inhibitor”, respectively, and it is possible that there may be differences in safety between the two drugs. The safety of these drugs will be evaluated for the future by the postmarketing surveillance for molecularly targeted drugs for psoriasis of the Japanese Dermatological Association.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, PsoriaticJanus Kinase InhibitorsPsoriasisHumansCytokinesInterleukin-6Janus Kinase 1Janus Kinase 2TYK2 Kinase

Stichwörter der Autor:innen

JAK1 inhibitorTYK2 inhibitordeucravacitinibpsoriasisupadacitinib

Substanzen

CytokinesInterleukin-6JAK1 protein, humanJanus Kinase 1Janus Kinase 2Janus Kinase InhibitorsTYK2 KinaseTYK2 protein, human

Autor:innen und Institutionen

  • Department of Dermatology, Nippon Medical School, Tokyo, Japan.
  • Department of Dermatology, Tokai University School of Medicine, Isehara, Japan.
  • Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.
  • Kojinkai Sapporo Skin Clinic, Sapporo, Japan.
  • Department of Dermatology, NTT Medical Center Tokyo, Tokyo, Japan.
  • Department of Dermatology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.

ORCID-Profile: Hidehisa Saeki, Akihiko Asahina, Shinichi Imafuku, Yukari Okubo, Mayumi Komine, Hideshi Torii, Akimichi Morita

Zitieren

APA

Saeki, H., Mabuchi, T., Asahina, A., Abe, M., Igarashi, A., Imafuku, S., Okubo, Y., Komine, M., Takahashi, K., Torii, H., Morita, A., Yotsuyanagi, H., Watanabe, A., Ohtsuki, M., & Committee for reviewing the safety of molecularly targeted drugs for psoriasis, Japanese Dermatological Association (2023). English version of Japanese guidance for the use of oral Janus kinase inhibitors ( JAK1 and TYK2 inhibitors) in the treatments of psoriasis. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.16797

Vancouver

Saeki H, Mabuchi T, Asahina A, Abe M, Igarashi A, Imafuku S, et al. English version of Japanese guidance for the use of oral Janus kinase inhibitors ( JAK1 and TYK2 inhibitors) in the treatments of psoriasis. The Journal of Dermatology. 2023. doi:10.1111/1346-8138.16797

BibTeX
@article{Saeki2023,
  author = {Saeki, Hidehisa and Mabuchi, Tomotaka and Asahina, Akihiko and Abe, Masatoshi and Igarashi, Atsuyuki and Imafuku, Shinichi and Okubo, Yukari and Komine, Mayumi and Takahashi, Kenzo and Torii, Hideshi and Morita, Akimichi and Yotsuyanagi, Hiroshi and Watanabe, Akira and Ohtsuki, Mamitaro and Committee for reviewing the safety of molecularly targeted drugs for psoriasis, Japanese Dermatological Association, Committee for reviewing the safety of molecularly targeted drugs for psoriasis, Japanese Dermatological Association},
  title = {English version of Japanese guidance for the use of oral Janus kinase inhibitors ( JAK1 and TYK2 inhibitors) in the treatments of psoriasis},
  journal = {The Journal of Dermatology},
  year = {2023},
  doi = {10.1111/1346-8138.16797}
}
Kostenlos starten →